IMMUNO-ONCOLOGY

免疫肿瘤学计划传统上代表了基础科学力量的主要焦点， AECC和上次CCSG审查被评为优秀。从那时起，该计划大大 通过成员的变化，现有成员研究的发展， 和招聘新的教师，其中几个是医生，科学家，到学院，这 程序.这些变化是自然进化计划成员的研究和对 上一个摘要声明。免疫肿瘤学计划的目标是：1）确定缺陷如何 在靶向产生抗体所需的免疫球蛋白基因的基因组不稳定性中 多样性导致突变和易位，导致B细胞淋巴瘤，并寻找方法， 避免这样的错误。一个目标是开发特异性靶向分子上不同的B细胞的治疗剂， 淋巴瘤变体。2)为了更好地了解抗原如何呈递给T细胞以及如何操作 这个过程可以增加肿瘤和癌症疫苗的免疫原性。3)开发和应用新的 免疫疗法，重点是放射免疫疗法和病毒诱导肿瘤的疫苗。平移 成就包括抗黑色素单克隆抗体放射性核素治疗的发展， 来自真菌黑色素的研究，将在2007年进入临床试验。研究主要集中在Bcl 6在细胞凋亡中的作用。 弥漫性大B细胞淋巴瘤的发病机制已经确定了肽抑制剂之间的相互作用 这个蛋白质和它的辅阻遏物。这种肽在临床前是有活性的，并且正在进一步开发中。 准备过渡到制药公司进行临床研究。招聘两名中学 该计划的成员将研究疫苗的临床和基础研究人员联系起来， 临床试验集中在宫颈瘤和其他实体瘤的治疗上。目前有16 来自11个部门的项目成员，其中11个是主要成员，由6个NCI（145万美元）支持 其他7项NIH赠款。自上次CCSG审查以来，已有176项癌症相关研究 该计划成员的论文，其中7%代表计划内，19%代表 方案间合作。

The Immuno-oncology Program has traditionally represented a major focus of basic scientific strength at AECC and at the last CCSG review was rated as excellent. Since that time this program has greatly increased its cancer focus through changes in membership, the evolution of research of existing members and the recruitment of new faculty, several of whom are physician-scientists, to the College and this Program. These changes were a natural evolution program member's research and a response to the previous summary statement. The goals of the Immuno-oncology program are: 1) To determine how defects in the targeting of the genomic instability of immunoglobulin genes required for the generation of antibody diversity lead to the mutations and translocations that cause B cell lymphomas and to search for ways to prevent such errors. One objective is to develop therapeutics targeted specifically to molecularly distinct Bcell lymphoma variants. 2) To better understand how antigen is presented to T cells and how to manipulate that process to increase the immunogenicity of tumors and cancer vaccines. 3) To develop and apply new immune therapies with a focus on radio-immunotherapy and vaccines to viral-induced tumors. Translational accomplishments include the development of a anti-melanin-mAb-radionuclide therapeutic, which emerged from studies on fungal melanin, that will enter clinical trials in 2007. Studies focused on the role of Bcl6 in the pathogenesis of diffuse large B cell lymphoma have identified a peptide inhibitor of the interaction between this protein and its corepressor. This peptide is active pre-clinically, and is being further developed in preparation for transition to a pharmaceutical company for clinical studies. The recruitment of two secondary members to this program has linked clinical and basic investigators who study vaccines within the context of clinical trials focused on the treatment of cervical neoplasia and other solid tumors. There are currently 16 program members from 11 departments, of whom 11 are primary members, supported by 6 NCI ($1.45M Direct) and 7 other NIH grants. Since the last CCSG review there have been 176 cancer-relevant research papers by members of this program of which 7% represent intraprogrammatic, and 19% represent interprogrammatic collaborations.